


## Technology Transfer Office (TTO) of BCIL is looking for suitable licensee for Novel Anti-inflammatory Peptide

Presently for treatment of inflammation, steroidal and non-steroidal products are used which have multiple side effects. The present technology **inhibits cellular** signaling (TLR-4 signaling inhibitors) instead of acting directly against bacterial pathogen.

The current technology being a peptide-based technology,

- ✓ Holds a great promise for the treatment of human and animal diseases because of their high specificity and potency and low incidence of toxicity.
- ✓ This technology can be used as a **therapeutic agent against inflammatory disorders** (such as sepsis, arthritis and anti-inflammatory drug).



### Applications-

- ✓ The earlier technologies use chemically synthesized pharmaceutical drugs, whereas the current technology uses **a cell permeable, therapeutic peptide** (Peptide mimetic).
- ✓ The technology is revolutionary as it is a novel therapeutic peptide with 29 amino acids.

**Stage of the Development- (TRLs 3)** Animal studies based upon mice model have been conducted to show efficacy, toxicity and safety profile

### Technology

Experiments in mice model indicates treatment with TB4-BBL2 does not induce any toxicity and the mice can tolerate high concentrations of the peptide (up to 40mg/kg). **The peptide treatment suppressed the production of pro-inflammatory cytokines in septicemia.**

For more information please contact us at

**BIOTECH CONSORTIUM INDIA LIMITED (BCIL)**

Dr. Shiv Kant Shukla,

Head Technology Transfer Office

& Dy. General Manager

V Floor, Anuvrat Bhawan, 210,

Deen Dayal Upadhyaya Marg, New Delhi-110002

Phone (Direct) : +91-11-23219058,

Email: [shuklashivkant@biotech.co.in](mailto:shuklashivkant@biotech.co.in) or [tto.bcil@biotech.co.in](mailto:tto.bcil@biotech.co.in)

Website: [www.biotech.co.in](http://www.biotech.co.in)